98%
921
2 minutes
20
Numerous cosmetic products claim to improve aging-induced wrinkles, and recent research has explored the potential of oral intake for wrinkle improvement. In our previous study, we investigated the effects of tomato seed extract (TSE), which contains lycoperoside H, on skin elasticity and its anti-inflammatory properties. The present study aimed to explore the anti-wrinkle effects of TSE through the inhibition of human neutrophil elastase (HNE), activated by inflammatory stimuli. The results indicated that TSE inhibits HNE (half maximal inhibitory concentration [IC]: 316 μg/mL), and that lycoperoside H contributes to this activity (IC: 37 mM). Additionally, several flavonoids found in TSE have been reported to exhibit HNE inhibitory effects. Based on these findings, we hypothesized that TSE supplementation could suppress excessive HNE activity in wrinkle-prone areas and potentially improve facial wrinkles. Therefore, we conducted a randomized, double-blind, placebo-controlled clinical trial with 45 healthy Japanese women (age range, 40-59 y) who had wrinkle grades of 3-5 around their eyes. The participants were randomly assigned to either a 200 mg/d TSE supplement (containing 1 mg of lycoperoside H) or a placebo for 12 wk. As a result, significant improvement in wrinkle grade was observed in the TSE group; however, improvements were also seen in the placebo group. Therefore, no significant differences in wrinkle reduction were found between the two groups. These findings suggest that the inhibition of HNE by TSE may have potential effects on the dermis, thereby offering new insights into the role of TSE in skin health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3177/jnsv.71.366 | DOI Listing |
Mol Ther Methods Clin Dev
September 2025
Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Recombinant adeno-associated viruses (rAAV) have emerged as a preferred strategy for gene delivery. However, the immune response to rAAV presents a major limitation, leading to serious adverse events in clinical trials. This study investigates the interaction between rAAV and the innate immune system.
View Article and Find Full Text PDFMov Disord
September 2025
Department of Neurology, Mass General Brigham, Boston, Massachusetts, USA.
Background: Light therapy (LT) in Parkinson's disease improves sleep. Specific LT parameters require further study, including optimal frequency.
Objectives: We aimed to determine if once- or twice-daily bright white light therapy (BWLT) improves sleep.
Aliment Pharmacol Ther
September 2025
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Background: Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas.
Aim: To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer.
Methods: Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory-wide electronic database in Hong Kong.
Proc Natl Acad Sci U S A
September 2025
Department of Psychology, University of Amsterdam, Amsterdam 1018 WS, The Netherlands.
Decision making and learning processes together enable adaptive strategic behavior. Animal studies demonstrated the importance of subcortical regions in these cognitive processes, but the human subcortical contributions remain poorly characterized. Here, we study choice and learning processes in the human subcortex, using a tailored ultra-high field 7T functional MRI protocol combined with joint models.
View Article and Find Full Text PDFInt J Gynaecol Obstet
September 2025
Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by leveraging the immune system's capacity to fight gynecologic cancer. This review summarizes the current status and future perspectives of ICIs in the treatment of cervical, endometrial, and ovarian cancers and rare tumors. ICIs have demonstrated significant efficacy in tumors with high tumor mutational burden and immune markers such as PD-L1 expression and microsatellite instability.
View Article and Find Full Text PDF